Ignite Creation Date:
2025-12-24 @ 1:51 PM
Ignite Modification Date:
2025-12-24 @ 1:51 PM
Study NCT ID:
NCT04426695
Status:
COMPLETED
Last Update Posted:
2023-01-27
First Post:
2020-06-08
Is Possible Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-06-10
Start Date Type:
ACTUAL
Primary Completion Date:
2021-05-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10-22
Completion Date Type:
ACTUAL
First Submit Date:
2020-06-08
First Submit QC Date:
None
Study First Post Date:
2020-06-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-05-05
Results First Submit QC Date:
None
Results First Post Date:
2022-07-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-25
Last Update Post Date:
2023-01-27
Last Update Post Date Type:
ACTUAL